Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis
NCT04680975 · Kadmon, a Sanofi Company · PHASE2 · terminated · last registry update 2023-06-05 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.” | – | Registry record, Kadmon, a Sanofi Company |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ROCK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-04-03Results posted on the registry: Aerie Pharmaceuticals, Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution (NCT05283395)
- 2023-11-22Phase 3 first posted: Sanofi, Belumosudil + Placebo (NCT06143891)
- 2023-11-01Results posted on the registry: BioNova Pharmaceuticals (Shanghai) LTD., BN101 (NCT04930562)
- 2023-10-13Phase 3 first posted: Sanofi, Belumosudil + Azithromycin (NCT06082037)
- 2023-09-21Phase 3 first posted: Singapore Eye Research Institute, Ripasudil (NCT06048380)
- 2023-08-30Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil (KD025) + Placebo (NCT03919799)
- 2023-08-30Also stopped (terminated): Kadmon, a Sanofi Company, Belumosudil (KD025) + Placebo (NCT03919799)
- 2023-06-28Results posted on the registry: Kadmon, a Sanofi Company, Belumosudil (KD025) (NCT02841995)
- 2023-04-24Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05826353)
- 2023-04-03Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05795699)
- 2023-02-27Results posted on the registry: Aerie Pharmaceuticals, Netarsudil ophthalmic solution 0.02% + Ripasudil hydrochloride hydrate ophthalmic solution 0.4% (NCT04620135)
- 2023-02-06Results posted on the registry: Price Vision Group, Netarsudil + Placebo (NCT03971357)
- 2023-02-06Also stopped (terminated): Price Vision Group, Netarsudil + Placebo (NCT03971357)
- 2022-12-21Phase 3 first posted: Wills Eye, Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] + Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud (NCT05660447)
- 2022-09-08Results posted on the registry: Kadmon Corporation, LLC, Belumosudil (NCT02688647)
- 2022-09-06Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05528172)
- 2022-09-01Results posted on the registry: Aerie Pharmaceuticals, Netarsudil Ophthalmic + Netarsudil Ophthalmic (NCT04498169)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision